论文部分内容阅读
目的:探讨血液系统恶性肿瘤病人化疗后应用rhG-CSF对中性粒细胞表型影响。方法:应用酶联免疫吸附法（ELISA）测定血浆rhG-CSF水平;应用免疫荧光技术和流式细胞仪分析检测中性粒细胞表型。结果:①急性白血病组和淋巴瘤组在应用rhG-CSF后的血浆rhG-CSF水平明显高于用药前的水平;②急性白血病组中性粒细胞CD64的表达明显高于正常对照组和感染组,在该组和淋巴瘤组中应用rhG-CSF后CD64的表达均较用药前有所增高;应用rhG-CSF前急性白血病组和淋巴瘤组CD62L的表达较正常对照组明显增高,而用药后其表达显著下调。急性白血病组和恶性淋巴瘤组应用rhG-CSF前、后,CD16、CD32、CD14和CD11b均无明显改变。结论:接受化疗的血液系统恶性肿瘤病人仍保留了对rhG-CSF的部分正常反应。
Objective: To investigate the effect of rhG-CSF on neutrophil phenotype after chemotherapy in patients with hematological malignancies. Methods: Plasma rhG-CSF levels were determined by enzyme-linked immunosorbent assay (ELISA). Neutrophil phenotypes were detected by immunofluorescence and flow cytometry. Results: ① The levels of plasma rhG-CSF in acute leukemia group and lymphoma group after rhG-CSF administration were significantly higher than those before treatment; ② The expression of neutrophil CD64 in acute leukemia group was significantly higher than that in normal control group and infection group , And the expression of CD64 in rhG-CSF group and lymphoma group was higher than that before treatment; the expression of CD62L in acute leukemia group and lymphoma group before rhG-CSF treatment was significantly higher than that in normal control group Its expression was significantly down-regulated. There was no significant change of CD16, CD32, CD14 and CD11b before and after rhG-CSF treatment in acute leukemia group and malignant lymphoma group. Conclusion: Patients with hematologic malignancies undergoing chemotherapy still retain some of the normal response to rhG-CSF.